Načítá se...
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
KRAS is frequently mutated in a variety of cancers including lung cancer. Whereas the mitogen-activated protein kinase (MAPK) is a well-known effector pathway of KRAS, blocking this pathway with MEK inhibitors is relatively ineffective. One major contributor to limited efficacy is attributed to the...
Uloženo v:
| Vydáno v: | Small GTPases |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5584737/ https://ncbi.nlm.nih.gov/pubmed/27392325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21541248.2016.1210369 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|